Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Sobi’s Xiapex recommended for NHS use by NICE

Sobi’s Xiapex recommended for NHS use by NICE

30th June 2017

Sobi has announced that its Dupuytren's disease therapy Xiapex has earned a recommendation from the National Institute for Health and Care Excellence (NICE).

The UK regulator has recommended that the pharmacological treatment for contracture of the fingers be made available for routine prescription among NHS patients in England.

Xiapex was approved by the European Commission for the treatment of Dupuytren's contracture in adult patients with a palpable cord in 2011, making it the first pharmacological treatment approved by the EU for treating this condition.

It has been designed to offer a viable alternative treatment option for patients who do not wish to undergo surgery, which can mean lengthy recovery times of between four and six weeks.

The NICE ruling follows recommendations for use in Wales by the All Wales Medicines Strategy Group in November 2011, and in Scotland by the Scottish Medicines Consortium in April 2012.

Neil Dugdale, general manager for Sobi in the UK and Ireland, said: "The availability of funding for Xiapex within NHS England is an important milestone for the Dupuytren's community in the UK, as healthcare providers can now offer people with contracture a non-invasive treatment option."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.ADNFCR-8000103-ID-801837423-ADNFCR

We have hundreds of jobs available across the Healthcare industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.